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Background: Diabetes mellitus (DM) is a major global public health problem. Lack of adherence to med-
ication causes suboptimal glycemic control increasing complication rates, costs and mortality. The objec-
tive of the study was to determine current antidiabetic medication adherence in Botswana and assess
associated factors so as to direct potential future interventions.
Materials and methods: A cross-sectional study among 376 randomly selected diabetic patients attending
a leading clinic in Gaborone, Botswana. Eight item Morisky Medication adherence questionnaire was
used to assess antidiabetic medication adherence. A structured questionnaire was also used to collect
information on factors influencing adherence including age, gender, education, type and duration of dia-
betes, treatment, complications and HIV status. Data were entered and analyzed using STATA Version 14,
and logistic regression performed.
Results: Over forty percent (41.8%) of patients were non-adherent to antidiabetic medications. Studied
sociodemographic characteristics and clinical variables did not affect adherence. HIV positive status
was associated with a statistically significant better adherence at multivariate analysis.
Conclusion: Adherence to antidiabetic medication was found to be suboptimal in a setting where medici-
nes are provided free of charge. Only HIV positivity was found to be significantly associated with better
adherence, probably due to effect of greater psychosocial support and counselling as part of HIV treat-
ment. There is a need to carry out studies to further improve understanding of factors associated with
medication adherence that are pertinent to Botswana and similar settings given the growing prevalence
of diabetes.
 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetic mellitus (DM) is a metabolic disorder, characterized by
elevated blood glucose levels. It is of growing public health impor-
tance.1 The prevalence of diabetes was estimated to increase from
171 million in 2000 to 366 million by the year 2030.2 However,
recent data from the International Diabetes Federation (IDF) sug-
gest that previous estimates have already been exceeded, with a
prevalence of 415 million by 2015 and estimated to reach 642 mil-
lion by 2040.3 The World Health Organization (WHO) also esti-
mated that there were 422 million adults living with DM in
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that the rise in the prevalence of DM is unevenly distributed with
over 70% of people with DM likely to live in developing countries,
particularly sub-Saharan Africa, a region already heavily burdened
by communicable diseases4–9 as well as non-communicable dis-
eases such as hypertension.10,11 DM accounted for 1.5 million
deaths in 2012 and rising.1
There is currently scarcity of data regarding the burden of DM in
Botswana. However, according to the International Disease Feder-
ation, there were 52,000 documented diabetic patients (approxi-
mate prevalence of 2.4%) in 2015 in Botswana.3 Data from the
STEPS survey conducted by the WHO in 2007 documented that
34.7% and 38.7% of the population of Botswana performed low
physical activity and were overweight respectively12; both vari-
ables being components of the metabolic syndrome leading to
Type 2 diabetes (T2DM). This suggests that the burden of DM in
Botswana may be higher than current estimates. It is well recog-
nized that various forms of DM peculiar to sub-Saharan Africa
exist, ranging from Type 1 and Type 2 DM, and malnutrition-
related diabetes to ketosis-prone diabetes. However, T2DM is by
far the most common type of diabetes, accounting for 90% of all
cases.13,14 T2DM occurrence is attributed to both modifiable and
non-modifiable factors including but not limited to social and
cultural behaviors, lack of physical activity, dietary habits,
urbanization and ageing.15,16 Patients with DM have increased
morbidity and mortality17–22 because of associated conditions as
a result of the complications of DM. These range from cardiovascu-
lar diseases, neuropathy, nephropathy, and bacteremia to
tuberculosis.23–26
The management of DM requires a multifaceted approach with
a focus on dietary modification, physical exercise and pharma-
cotherapy.27,28 Good adherence to treatment strategies is crucial
for the successful management of chronic asymptomatic condi-
tions such as hypercholesterolemia and hypertension.29–33 For
DM specifically, a combined approach of diet control, physical
exercise and medication helps achieve sufficient glycemic control
and avoids related short-term and long-term complications.34–38
Good control of blood pressure and regular use of statins helps
reduce cardio-vascular events and deaths.39,40 However, the
WHO estimates that only half of patients with chronic diseases
are medication adherent.41 Most of previous studies on adherence
to antidiabetic medications have shown low adherence patterns to
both pharmacotherapy and other aspects of diabetic care.33,42–45
Various factors are associated with non-adherence to medica-
tion in DM patients, which can be categorized as patient centered,
therapy-related or healthcare system related.46,47 Patient-centered
factors include sociodemographic (age, gender and educational
level) factors, psychological factors including motivation towards
therapy taking, patient-prescriber relationship and patient knowl-
edge.42,48,49 Therapy-related factors include route, type and dura-
tion of treatment, complexity of treatment especially as patients
may be on multiple medicines, cost of medication especially if
co-payment is an issue and adverse effects.50–55 Healthcare system
factors include availability and accessibility of health care, and the
health provider-patient interactions.56
Despite the fact that many studies have been performed glob-
ally on adherence to antidiabetic medicines, and the majority have
showed varied non-adherence from low to high,28 we felt it was
justified to undertake a study in Botswana, as each community
has its own culture and lifestyle that may affect adherence in a dif-
ferent way.57 This is especially the case in Botswana with its high
prevalence of HIV at over 22% of the adult population, with higher
rates especially among women.58 At one stage, nearly 50% of
women aged 30–34 years had HIV59; however, rates are now
decreasing among the young.58 High prevalence rates are also seen
in other African countries, with higher rates generally amongwomen than men.60,61 This is important as this will appreciably
enhance the pill burden in patients with both DM and HIV.
This study was conducted to determine the magnitude of
antidiabetic medication adherence and assess associated factors
among both patients with Type 1 and Type 2 DM in a tertiary dia-
betic clinic in Gaborone including those with HIV. If there were
concerns with medication adherence in this specialized setting,
this would reflect concerns generally throughout Botswana. The
findings may also be of interest to other African countries with
high prevalence rates of HIV and growing rates of DM to help
improve their future management of these patients.2. Materials and methods
2.1. Study design and setting
This was a cross-sectional study conducted at Block 6 clinic, a
tertiary clinic specializing in the treatment of patients with both
Type 1 and Type 2 DM. Block B clinic is situated in Gaborone, the
capital city of Botswana, with a population of approximately
200,000. The clinic offers various services to over estimated 3000
diabetic patients. Services include physician consultations, health
education, eye and foot screening and the issuing of medicines.
Medicines are provided free-of-charge so co-payment is not an
issue affecting medication adherence.62,63 On average 1800–2000
diabetic patients visit the clinic monthly for various reasons, of
which an average of 1400 patient visits are physician
consultations.
2.2. Study population
A total of 376 patients were randomly selected over the course
of two months from 21st July 2015 to 21st September 2015. At the
time of data collection, approximately 70 patients attended the
clinic each day. Inclusion criteria: All patients above the age of
21 years who attended the clinic on working days (Monday to
Friday) and who consented to participate in the study. Exclusion
criteria: Patients with decision impaired illnesses such as mental
illness, including schizophrenia, bipolar disorder and dementia,
were excluded from the study along with those who refused to
take part.
2.3. Sample size
Sample size was calculated using the formula for cross-
sectional study using a prevalence of non-adherence to chronic
medication of 67%64,65 with standard score of 95% confidence level
and margin of error of 5% giving a minimum sample size of 340
patients.
2.4. Data collection
Data were collected by two research assistants, who were qual-
ified nurses, and trained in interview techniques prior to the study.
A list of patients attending the clinic was obtained from the nurses
doing vital signs, and a coin was tossed for the first 10 patients on
the list to randomly obtain the first patient for each day of data col-
lection. From there, every 5th patient was subsequently
approached for consent to participate in the study. In case of
refusal, either tossing the coin was repeated or a subsequent
5th patient was approached, without affecting the prior order,
to ensure a random sample. About 8–10 patients were recruited
on each week day of recruitment. A structured questionnaire,
which was pre-tested, was used to obtain information on the
socio-demographic characteristics, as well as factors affecting
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medication was determined during the interview using the Mor-
isky 8-Item Medication Adherence Questionnaire (Box 1). All ques-
tions, except for the last question, were answered with a yes/no
response, with corresponding 1 and 0 value. Overall adherence to
medication was categorized based on patients’ responses, accord-
ing to the following scores: >2 = low adherence; 1 or 2 = medium
adherence; 0 = high adherence.66–68Box 1 Morisky 8-Item Medication Adherence
Questionnaire67
 Do you sometimes forget to take your medicine? (Y = 1;
N = 0)
 People sometimes miss taking their medicines for reasons
other than forgetting. Thinking over the past 2 weeks, were
there any days when you did not take your medicine?
(Y = 1; N = 0)
 Have you ever cut back or stopped taking your medicine
without telling your doctor because you felt worse when
you took it? (Y = 1; N = 0)
 When you travel or leave home, do you sometimes forget to
bring along your medicine? (Y = 1; N = 0)
 Did you take all your medicines yesterday?(Y = 0; N = 1)
 When you feel like your symptoms are under control, do
you sometimes stop taking your medicine? (Y = 1; N = 0)
 Taking medicine every day is a real inconvenience for some
people. Do you ever feel hassled about sticking to your
treatment plan? (Y = 1; N = 0)
 How often do you have difficulty remembering to take all
your medicine? (A = 0; B–E = 1 where A. Never/rarely; B.
Once in a while; C. Sometimes; D. Usually; E. All the time).
Table 1
Sociodemographic characteristics of the study partic-










Age, mean (SD) 56.5 (13.7)
Education level
No formal school 70 (18.6)
Less than primary school 78 (20.7)
Primary school completed 103 (27.4)
Secondary school completed 77 (20.5)
College/University completed 42 (11.2)
Post-graduate degree 6 (1.6)
Marital statusClinical characteristics, past medical history and history of doc-
umented diabetic complications were obtained from patients’
charts. Further information on the patients’ history was obtained
from outpatient charts. Results of previous laboratory investiga-
tions (undertaken within six months of the index visit) such as gly-
cated haemoglobin were obtained from the Integrated Patients
Management System (IPMS). As regards the HIV status, patients
were categorized as either HIV negative/-positive/-unknown
according to their response of being tested with evidence of docu-
mentation in the past year or known HIV seropositive results
recorded in the IPMS.
Physical examination of patients by clinic staff is undertaken
routinely. This involves measuring weight, using a calibrated
weighing scale and entering the data onto the charts. The height
of each patient taking part was measured by research assistants
using calibrated height scale to enable calculations of the Body
Mass Index (weight in kg/height in m2).
Patients’ ages were recorded as whole numbers, e.g. if a patient
was 50 years and 9 months, the age would be recorded as 50 years.Never married 102 (27.1)







Normal weight 65 (19.3)
Overweight 98 (29.2)
Obese 168 (50)
SD: Standard deviation.2.5. Data management and analysis
Data were entered and analyzed using STATA Version 14. To
assess any associations, both univariate and multivariate logistic
regression with odds ratios (OR) and 95% confidence interval (CI)
were performed. Medication adherence was dichotomized as
either adherent (Morisky score = 0/high adherence) or non-
adherent (Morisky score 1/low and medium adherence). The
dichotomization in this study was according to previous studiesthat used Morisky scale and categorized any score above zero as
non-adherent.69–71 A p-value of less than 0.05 was considered sta-
tistically significant.
3. Ethical considerations
Ethical clearance to conduct the study was obtained from the
University of Botswana Ethics Committee and the Institutional
Review Board (IRB) as well as the Ethics Committee at Princess
Marina Hospital. Ethical clearance was also secured from the Bots-
wana Ministry of Health Research Unit. All patients provided writ-
ten informed consent for participation.
4. Results
4.1. Baseline socio-demographic characteristics
A total of 376 patients were interviewed after excluding 4
patients who refused informed consent. The majority of patients
were female (69.1%). The mean age of patients was 56.5
(SD: 13.7) years with a median duration of DM of 5.0 years. Most
of the study participants were either overweight or obese account-
ing for 29.2% and 50.0% respectively (Table 1).
4.2. Clinical and medication characteristics of study participants
Most of the interviewed patients were T2DM, accounting for
353 of the 376 patients (93.9%). As regards the duration of
diagnosed diabetes, nearly half of the patients (46.8%) had been
diagnosed less than 5 years ago. Over 80% of patients were either
only on oral hypoglycemic agents or on a combination of oral
hypoglycemic agents and insulin. The majority (81.8%) of patients
had diabetic complications documented in their outpatients’
Table 2
Clinical and medication characteristics of study participants (n = 376).
Clinical and medication characteristics n (%)
Type of diabetes mellitus
Type 1 23 (6.1)
Type 2 353 (93.9)
Duration of diabetes
<5 years 176 (46.8)
5–10 years 89 (23.7)
>10 years 93 (24.7)
Missing 18 (4.8)
Modality of treatment for diabetes
Oral hypoglycemic agents (OHA) 224 (59.6)
Insulin 51 (13.6)
Both OHA and insulin 101 (26.8)







Diabetic complications (multiple responses)
Eye complications-retinopathy 142 (37.4)
Skin complications with or without itching 133 (35.0)
Postural hypotension 116 (30.5)
Palpitations 113 (29.7)
Gastroparesis 77 (20.3)
Erectile dysfunction 59 (15.5)
Neuropathy 55 (14.5)
Heart failure 32 (8.4)
Diabetic foot/hand with or without ulcer 23 (6.1)







Prevalence of adherence to antidiabetic medication
according to Morisky scale (n = 376).
Adherence category (Morisky score) n (%)
High adherence (0) 219 (58.2)
Medium adherence (1–2) 91 (24.2)
Low adherence (>2) 66 (17.6)
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5 years. Nearly two thirds (62.2%) of patients were HIV negative
and for 27.7% the HIV-status was unknown (Table 2).
4.3. Prevalence of antidiabetic medication adherence
The prevalence of high adherence to antidiabetic medication
according to the Morisky scale was 58.2%. Medium and low adher-
ence was 24.2% and 17.6% respectively accounting for 41.8% of
non-adherent group (Table 3).
4.4. Factors associated with antidiabetic adherence
Several factors, including sociodemographic characteristics
(age, gender, educational level and marital status) and clinical
and medication characteristics (HIV status, type of diabetes, dura-
tion of diabetes and modality of treatment) were analyzed to
determine any association with adherence to antidiabetic medica-
tion. For this purpose as mentioned, patients were categorized as
either adherent (Morisky score = 0/high adherence) or non-
adherent (Morisky score 1/low and medium adherence).For all the studied factors, only HIV-positive status was associ-
ated with high antidiabetic medication adherence; 30/38 (78.9%) of
HIV-positive patients were adherent to antidiabetic medication
compared to 122/234 (52.1%) (p-value = 0.017, AOR = 0.31, 95%
CI = 0.13–0.74) (Table 4).4.5. Association between antidiabetic medication adherence and
glycemic control
Overall, the analysis of the extent of antidiabetic medication
adherence to glycemic control from using glycated haemoglobin
(HbA1c levels) revealed no statistically significant association
(p-value = 0.09; COR = 1.45; 95% CI = 0.94–2.23). The association
between HIV positive status and better antidiabetic medication
was still significant in multivariate analysis (Table 5).5. Discussion
The duration of diagnosed diabetes was less than 5 years for
nearly half of the patients in this study, however; over 80% of
patients had documented complications in their charts. This
implies either the possibility of late diagnosis, calling for an
increase in screening programmes in the community especially
given the likelihood of the high prevalence rates of diabetes in
Botswana; alternatively poor adherence to combined treatment
approaches, including diet, exercise and medicines. Screening pro-
grams to diagnose diabetes mellitus earlier will help reduce both
microvascular and macrovascular complications as well as associ-
ated costs.34,72,73
Overall, adherence to antidiabetic medication was found to be
suboptimal with only 57.6% of patients demonstrating high adher-
ence (Table 3). This is higher though than in a Nigerian study using
the same instrument which reported only 40.6% of patients with
high medication adherence.74 While other studies have shown
costs, i.e. patient co-payments, to significantly affect adherence
to antidiabetic medication,50,55,75 the same cannot be said for Bots-
wana as medication for the treatment of DM are provided free of
charge. However, this rate of adherence was low compared to
other studies undertaken in Nigeria (72.5%),76 as we; as Uganda
(71%)55 and Tanzania (71.2%).50 The reason for the differences seen
may partly be explained by the different methodologies used to
estimate adherence rates in the various studies. These studies typ-
ically used patients’ recall on adherence or pill counts. However,
we feel that the use of the Morisky scale is justified in our study
to estimate adherence as this methodology is well validated and
has been used widely.77 In any event, our findings mean more edu-
cational and other input needs to be undertaken in the clinics to
improve adherence rates in Botswana.
Interestingly in our study, high adherence to diabetes medicines
was not significantly associated with better glycemic control,
which is similar though to other studies.50,78,79 However, it is
important to point out that only antidiabetic medication adherence
was studied and not other factors including physical exercise and
diet, in addition to HIV medication.80–82
Other studies have also shown contrasting results on factors
affecting adherence to antidiabetic medication, with factors rang-
ing from demographic characteristics such as age, gender and level
of education55,83–85 to clinical and medication factors such as dura-
tion of diagnosed diabetes, modality of treatment and complexity
of treatment.40 The findings of our study (Table 4) did not reveal
any association to any of these commonly studied variables. This
may again reflect different methodologies and settings, and needs
further investigation.
Patients with an HIV-positive status in this study were found to
be more adherent than those with an HIV-negative or –unknown
Table 4
The relationship between sociodemographic, clinical, and other characteristics on adherence to antidiabetic medication.
Characteristics Adherenta Non-adherenta Crude OR (95% CI) p-Value
Age group 0.43
<36 24 8 1 (Ref)
36–50 41 37 2.72 (1.82–9.04)
51–65 96 67 2.21 (0.64–7.66)
>66 54 49 2.31 (0.62–8.62)
Sex 0.50
Male 71 45 1 (Ref)
Female 144 116 1.18 (0.73–1.93)
Education level 0.16
No/primary 148 103 1 (Ref)
Secondary or higher 67 58 1.47 (0.86–2.50)
Marital status 0.73
Married/cohabiting 105 80 1 (Ref)
Single/separated/divorced/widowed 110 81 1.08 (0.69–1.69)
HIV status 0.01
Negative 122 112 1 (Ref)
Positive 30 8 0.29 (0.12–0.69)
Unknown 66 38 0.68 (0.41–1.41)
Type of diabetes 0.56
Type 1 17 6 1 (Ref)
Type 2 198 155 0.63 (0.14–2.91)
Diabetes duration 0.92
<5 years 114 64 1 (Ref)
5–10 years 50 41 1.53 (0.89–2.65)
>10 years 47 46 1.83 (1.02–3.28)
Modality of treatment 0.28
OHA 127 97 1 (Ref)
Insulin 38 13 0.24 (0.05–1.18)
Both OHA and Insulin 57 44 0.46 (0.11–1.86)
Note: 4 patients with no Morisky score results excluded from analysis.
a Adherent: Morisky score = 0/high adherence; Non-adherent: Morisky score 1/low and medium adherence.
Table 5
Logistic regression output showing factors associated with antidiabetic medication
adherence.
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health care system. A patient in a diabetes clinic in Botswana was
previously overheard, saying in Setswana (local language), ”Go ka
bo go ne go le botoka go nna le HIV gona le bolwetse jwa sukiri”,
and when translated to English, ‘‘It would have been better if I had
HIV instead of diabetes.”.86 These words imply that diabetic patients
may feel they are not cared for as well as their HIV positive coun-
terparts. Screening for diabetes does not take place routinely;
hence patients with diabetes are often diagnosed and come to
the attention of specialist clinics only when they have already
developed complications.84 This will be explored further in future
research in view of the growing prevalence of diabetes in Bots-
wana, the need to ensure high adherence with prescribed treat-
ment approaches, and the fact that our study revealed a positive
association between HIV-positive status and better antidiabetic
medication adherence (Table 5). Some of the ‘unknowns’ (Table 5)
are also likely to be HIV positive in view of the prevalence in
Botswana.58 This phenomenon may possibly be explained by the
fact that HIV positive patients receive counseling sessions and psy-
chosocial support to enhance their antiretroviral medication
adherence. As a result, also improving antidiabetic medication
adherence, despite an appreciably increased pill burden. This will
also be the subject of future research projects.6. Study limitations
Our findings should be interpreted with caution. Firstly, we only
conducted the study in one centre in Botswana. However, this was
a leading clinic in Botswana and if poor adherence rates were seen
here, the situation may be worse in other centres.
We also did not include psychosocial factors in our question-
naire. We acknowledge that other published studies have shown
the role of factors including language, health literacy, social sup-
port, cultural factors and stigma, which can contribute to low
adherence.57 This will be investigated further in future studies.
Our study also only included aspects of pharmacotherapy. The
importance of the other two components of diabetes care, namely
physical exercise and dietary modifications, cannot be over stated
in their role to enhance glycemic control and improve the outcome
of patients with DM.
However, we do believe that this first study on antidiabetic
medication adherence in Botswana including patients with con-
comitant HIV, and will encourage further research to improve
future patient management in Botswana, given the current low
adherence rates and high numbers of patients with DM, having
complications early in their disease state.
7. Conclusion
About two in every five patients was non-adherent to antidia-
betic medication. This is quite a significant number especially in
this specialist clinic in Botswana where medicines are provided
monthly at no cost to the patients. Only HIV-positive status was
found to be significantly associated with better medication adher-
ence, probably due to the effect of greater patient support and
counseling offered at HIV clinics, despite appreciably increasing
108 G.M. Rwegerera et al. / Alexandria Journal of Medicine 54 (2018) 103–109the pill burden. This has important implications for improved man-
agement of patients with DM in Botswana in the future and will be
the subject of further research along with exploring psychosocial
factors associated with medication adherence that are pertinent
to the Botswana setting. There is also a need for greater screening
of patients to identify patients earlier to reduce complication rates.
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